drugset / Trial / NCT02140333
Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether 100mg erlotinib had similar effect compared with 150mg erlotinib in NSCLC patients with EGFR mutation in China.
Timeline
- Start
- 2013-08
- Primary completion
- 2018-08
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 100 mg | — |
| Subject | Erlotinib | Small molecule | 150 mg | — |